List of Excipients in Branded Drug OMEPRAZOLE/SODIUM BICARBONATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Prasco Laboratories	OMEPRAZOLE/SODIUM BICARBONATE	omeprazole, sodium bicarbonate	66993-412	CROSCARMELLOSE SODIUM
Prasco Laboratories	OMEPRAZOLE/SODIUM BICARBONATE	omeprazole, sodium bicarbonate	66993-412	SODIUM STEARYL FUMARATE

Generic Drugs Containing OMEPRAZOLE/SODIUM BICARBONATE

Company	Ingredient	NDC	Excipient
Par Pharmaceutical Inc	omeprazole and sodium bicarbonate	49884-269	PEACH
Par Pharmaceutical Inc	omeprazole and sodium bicarbonate	49884-269	PEPPERMINT
Par Pharmaceutical Inc	omeprazole and sodium bicarbonate	49884-269	SUCRALOSE
Par Pharmaceutical Inc	omeprazole and sodium bicarbonate	49884-269	SUCROSE

What are the Most Frequently-Used Excipients in OMEPRAZOLE/SODIUM BICARBONATE?

# Of NDCs	Excipient
4	PEACH
4	PEPPERMINT
4	SUCRALOSE
4	SUCROSE

Omeprazole/Sodium Bicarbonate Excipient Strategy and Commercial Opportunities

Last updated: August 3, 2026

Omeprazole/sodium bicarbonate is an immediate-release proton-pump inhibitor platform that uses sodium bicarbonate as both an alkalizing excipient and a gastric-acid neutralizer. The formulation avoids the enteric coating used in conventional delayed-release omeprazole products. Its commercial value is concentrated in rapid onset, simplified dosage forms, bedtime dosing, suspension delivery, and differentiation for patients who have difficulty swallowing conventional capsules.

The main commercial products are Zegerid prescription capsules and powder for oral suspension, plus OTC omeprazole/sodium bicarbonate products. The active ingredient is omeprazole, while sodium bicarbonate protects omeprazole from acid degradation before absorption and raises gastric pH. The formulation is technically accessible, but meaningful differentiation requires control of dose uniformity, moisture, bicarbonate loading, packaging, taste, and regulatory positioning.

What is the omeprazole/sodium bicarbonate formulation strategy?

The formulation combines omeprazole with a substantial quantity of sodium bicarbonate. Typical marketed strengths include:

Product type	Omeprazole dose	Sodium bicarbonate dose	Key formulation purpose
Prescription capsule	20 mg	1,100 mg	Immediate-release acid protection
Prescription capsule	40 mg	1,100 mg	Higher-strength treatment
Oral suspension	20 mg	Approximately 1,680 mg per packet, depending on product	Rapid dispersion and acid neutralization
OTC capsule or tablet products	Commonly 20 mg	Commonly about 1,100 mg	Consumer bedtime heartburn treatment

The exact excipient system varies by manufacturer and dosage form. The commercial design problem is not simply to mix omeprazole with bicarbonate. Omeprazole is acid-labile, and its chemical stability depends on maintaining an alkaline microenvironment through manufacturing, storage, reconstitution, and gastric exposure.

The formulation has four functional requirements:

1. Maintain an alkaline environment around omeprazole.
2. Prevent moisture-driven degradation during storage.
3. Deliver a reproducible omeprazole dose.
4. Produce acceptable powder flow, capsule fill, dispersion, and patient tolerability.

Sodium bicarbonate performs two related functions. It buffers the formulation against gastric acid and neutralizes existing gastric acid. That mechanism supports immediate-release delivery without the enteric-coated pellets used in standard omeprazole delayed-release capsules. The tradeoff is a high excipient mass and a greater dependence on physical stability and packaging.

What excipients are used in omeprazole/sodium bicarbonate products?

Public labeling identifies sodium bicarbonate as the principal functional excipient. Other excipients depend on the dosage form and manufacturer.

Capsule excipients

A capsule formulation may include:

• Sodium bicarbonate
• Lactose or another diluent
• Crospovidone or a disintegrant
• Colloidal silicon dioxide or a flow aid
• Hypromellose or gelatin capsule shell
• Printing inks and colorants

The exact composition must be verified against the applicable FDA labeling and product-specific inactive-ingredient records. Prescription Zegerid capsules are generally described as containing omeprazole, sodium bicarbonate, and capsule or manufacturing excipients, while OTC versions use different formulation designs and may be delivered in capsules, tablets, or chewable formats [1,2].

Powder-for-suspension excipients

Powder suspension products can include:

• Sodium bicarbonate
• Sweeteners
• Flavoring agents
• Suspending agents
• Wetting agents
• Bulking agents
• Flow conditioners

The powder must disperse rapidly in water without producing unacceptable foaming, clumping, sedimentation, or taste. Sodium bicarbonate can create carbon dioxide during acid neutralization and may influence mouthfeel and patient acceptance.

Excipient selection priorities

Excipient attribute	Commercial relevance
Low moisture content	Limits omeprazole degradation
Alkaline compatibility	Maintains formulation stability
Low hygroscopicity	Improves capsule and powder shelf life
Consistent particle size	Supports blend uniformity
Low chemical reactivity	Reduces degradation pathways
Good flow properties	Improves high-dose capsule filling
Taste masking	Supports OTC and pediatric opportunities
Global regulatory acceptance	Reduces registration complexity

Sodium bicarbonate has a relatively high dose compared with the active ingredient. A 20 mg omeprazole dose paired with 1,100 mg sodium bicarbonate creates a formulation in which the excipient dominates the unit mass. That ratio affects manufacturing economics, swallowing burden, packaging, and product positioning.

How does sodium bicarbonate protect omeprazole?

Omeprazole is unstable under acidic conditions. Sodium bicarbonate creates an alkaline environment that reduces acid-mediated degradation before absorption. The immediate-release formulation allows omeprazole to pass through the stomach in a protected state and then be absorbed in the small intestine.

The strategy differs from conventional delayed-release omeprazole:

Attribute	Omeprazole/sodium bicarbonate	Conventional delayed-release omeprazole
Release design	Immediate release with alkaline protection	Enteric-coated granules or pellets
Main protective mechanism	Sodium bicarbonate and alkaline microenvironment	Enteric polymer coating
Dosage-form mass	High because of bicarbonate	Usually lower excipient mass per dose
Manufacturing complexity	Blend and moisture control	Pellet coating and multiparticulate processing
Bedtime use	Commercially differentiated	Traditionally dosed before meals
Reconstitution option	Available in powder products	Less common
Key stability risk	Moisture and alkaline microenvironment control	Coating integrity and moisture protection

The formulation does not eliminate the need for pharmacokinetic and clinical control. Immediate release changes the exposure profile and can support bedtime dosing, but labeling remains product-specific. Prescription Zegerid labeling includes dosing instructions that differ from conventional delayed-release omeprazole products [1].

What patent protection covers omeprazole/sodium bicarbonate products?

The principal intellectual-property concept is the combination of omeprazole with an alkaline compound, particularly sodium bicarbonate, in an immediate-release dosage form.

Formulation patent scope

Historical patent families associated with the platform have covered combinations involving:

• Omeprazole or related benzimidazole proton-pump inhibitors
• Sodium bicarbonate or another alkaline compound
• Immediate-release capsules
• Powder formulations
• Stable pharmaceutical compositions
• Methods of reducing acid degradation
• Treatment of acid-related gastrointestinal disorders

U.S. patents associated with Santarus and related entities protected aspects of immediate-release omeprazole/sodium bicarbonate compositions. The principal early patent estate was filed in the 1990s and early 2000s, placing many core composition claims in the 2020-2022 expiration range, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and claim-specific status [3-5].

Patent and exclusivity assessment

IP category	Relevance to current competition
Core omeprazole/sodium bicarbonate composition claims	Many historical rights have reached or approached expiration
Specific capsule or powder formulations	Potentially expired, abandoned, or limited by claim scope
Manufacturing and moisture-control claims	May create narrower process barriers
Method-of-use claims	Can affect labeled indications and substitution strategy
Trade secrets	Blend order, moisture control, packaging, and scale-up methods may remain important
Trademark rights	Zegerid and related brands remain separate from patent rights

A freedom-to-operate review must examine live claims, not only patent-family titles. Patent expiration does not automatically eliminate risk from later-filed formulation, manufacturing, packaging, or method-of-use patents. The relevant analysis should include U.S. Patent and Trademark Office status, Orange Book listings, patent-term calculations, terminal disclaimers, and any litigation or settlement history.

What is the Orange Book status of omeprazole/sodium bicarbonate?

Prescription Zegerid products were approved under NDA 021849, associated with Santarus and later commercialized through successor companies including Salix Pharmaceuticals and Valeant Pharmaceuticals, now Bausch Health [1,6].

The Orange Book is relevant because approved prescription products may have listed patents and therapeutic-equivalence codes. The practical regulatory questions are:

• Whether a reference-listed drug has current patent listings.
• Whether an ANDA applicant must make a Paragraph IV certification.
• Whether a listed patent has expired or has been delisted.
• Whether the proposed generic uses the same dosage form, strength, route, and labeling.
• Whether the reference product has unexpired exclusivity separate from patent protection.

For a mature product such as omeprazole/sodium bicarbonate, generic risk is primarily controlled by formulation complexity and market economics rather than by the original core patent alone. An ANDA applicant may still face patent certifications if live formulation or method-of-use patents remain listed. FDA Orange Book data and current FDA labeling should be used for product-specific determinations [1,6].

When does omeprazole/sodium bicarbonate lose exclusivity?

The original U.S. prescription product received FDA approval in 2004. The basic five-year new chemical entity exclusivity period therefore ended in 2009, assuming standard NCE treatment. Any pediatric exclusivity or other extension would have to be evaluated from FDA records.

The original core formulation patents were filed substantially earlier than approval. Many key rights have therefore expired, or are close to expiration, depending on the specific patent and adjustment. Commercial exclusivity now depends on:

• Remaining listed patents
• Regulatory exclusivity for any later-approved product
• Brand recognition
• Distribution access
• Manufacturing consistency
• OTC consumer marketing
• Formulation know-how
• Product-specific labeling

A generic entrant could pursue several approaches:

1. Copy the reference capsule using the same active and bicarbonate concept.
2. Develop an alternative immediate-release powder.
3. Develop a tablet, chewable, or orally disintegrating product.
4. Use a different alkalizing system.
5. Launch an OTC product under a separate monograph or approved application pathway.

What Paragraph IV challenges and litigation affect the product?

Paragraph IV risk is product-specific and depends on the active Orange Book listing at the time of ANDA submission. A Paragraph IV certification alleges that a listed patent is invalid, unenforceable, or not infringed. The reference sponsor may file infringement litigation within 45 days, triggering an automatic 30-month stay under the Hatch-Waxman framework, subject to statutory exceptions and court action [7].

For omeprazole/sodium bicarbonate, the principal historical litigation risk centered on whether generic products practiced claims covering:

• The immediate-release combination
• The quantity or function of sodium bicarbonate
• Stability characteristics
• Specific dosage forms
• Methods of administering the product

The age of the core product reduces the likelihood that the original composition claims alone will prevent generic entry. The higher-risk areas are later patents with narrower claims, especially those directed to a commercial formulation, manufacturing process, or specific method of use.

No current litigation conclusion should be drawn from the existence of an old patent family. Litigation status must be checked against PACER, court dockets, FDA Orange Book updates, and USPTO records.

Which companies are competing in omeprazole/sodium bicarbonate?

The competitive field includes branded, authorized-generic, prescription-generic, and OTC manufacturers.

Competitive segment	Representative participants	Commercial basis
Prescription branded product	Bausch Health and affiliated commercial entities	Zegerid brand, established prescriber recognition
Prescription generic	ANDA applicants and generic manufacturers	Price competition and formulary access
OTC acid reducers	Private-label and branded manufacturers	Retail distribution and consumer advertising
Alternative PPIs	AstraZeneca, generic manufacturers, and OTC sellers	Omeprazole, esomeprazole, lansoprazole, pantoprazole
Alternative delivery systems	Specialty and consumer-health companies	Chewables, tablets, suspensions, and orally disintegrating formats

The strongest competitive threat comes from conventional OTC omeprazole and other proton-pump inhibitors that have lower formulation mass and broad retail availability. The sodium bicarbonate platform must therefore compete on use case rather than only active ingredient.

What commercial opportunities exist for new excipient strategies?

Bedtime acid control

Immediate-release omeprazole/sodium bicarbonate is positioned around bedtime dosing and nocturnal heartburn. A new product can differentiate through lower sodium bicarbonate exposure, improved palatability, smaller dosage form, or faster dispersion.

Low-sodium formulations

The sodium load is a commercial limitation. A 1,100 mg sodium bicarbonate dose contains a substantial amount of sodium. A reformulation that preserves alkaline protection with less sodium could target consumers concerned about sodium intake, subject to clinical and regulatory support.

Possible strategies include:

• More efficient alkaline buffering
• Alternative carbonate or bicarbonate salts
• Multicomponent buffering systems
• Microenvironmental alkalization
• Protective excipient matrices
• Reduced-dose bicarbonate with improved packaging and process controls

A substitute alkalizer may create new patentable subject matter, but it also introduces new safety, tolerability, compatibility, and regulatory questions.

Powder and sachet products

Powder-for-suspension products offer opportunities for:

• Patients who cannot swallow capsules
• Care settings
• Hospital or institutional use
• Travel packaging
• Rapid reconstitution
• Pediatric or geriatric formulations, where clinically appropriate

The main development risks are taste, foaming, incomplete dispersion, stability after reconstitution, and dose loss on the container surface.

Chewable and orally disintegrating dosage forms

Chewable and orally disintegrating products could reduce swallowing barriers but create new formulation problems. Omeprazole’s acid sensitivity must be controlled in a dosage form exposed to saliva, humidity, and prolonged oral residence. Taste masking and alkaline mouthfeel are central development issues.

Pediatric and geriatric delivery

A flexible suspension or dispersible product may have value for patients with dysphagia. Pediatric development requires age-appropriate dosing, palatability, safety data, and a suitable regulatory pathway. The product cannot rely only on adult capsule data if the proposed indication, population, or administration method differs materially.

Combination therapy

Potential commercial extensions include combinations with:

• Alginate systems
• Antacids
• H2-receptor antagonists
• Barrier-forming agents
• Symptom-directed ingredients

Combination products increase patent and regulatory complexity. They also create potential labeling, interaction, stability, and reimbursement challenges. The most defensible opportunities are combinations that demonstrate a clinically meaningful advantage rather than simply adding an antacid.

How strong is the patent estate for a new omeprazole/sodium bicarbonate product?

The original platform estate is weaker than it was during the early commercial life of Zegerid because core composition rights have aged. A new entrant can still build a moderate patent position around product-specific improvements.

Patent target	Likely strength	Commercial value
Generic omeprazole plus sodium bicarbonate mixture	Low to moderate	Limited if core claims are expired
Reduced-sodium buffer system	Moderate	Supports differentiated product
Moisture-protective packaging	Moderate	Useful but often narrow
Specific powder particle engineering	Moderate	Can support manufacturability and stability
Taste-masked suspension	Moderate to strong	Valuable for OTC and dysphagia markets
Novel chewable or orally disintegrating system	Moderate to strong	Product differentiation
Manufacturing process with validated stability advantage	Moderate	Can create trade-secret and patent protection
New clinical use	Variable	Depends on evidence and claim scope

The best protection strategy combines patents with trade secrets. Patent claims should cover composition, dosage form, manufacturing process, packaging, and use where the evidence supports each category. Trade-secret controls should protect moisture limits, blend order, hold times, environmental conditions, and in-process acceptance criteria.

What manufacturing and IP barriers affect market entry?

The active ingredient is widely available, but the formulation is not operationally simple. Key manufacturing barriers include:

• Omeprazole segregation at low concentration
• High bicarbonate loading
• Blend uniformity
• Moisture uptake
• Carbon dioxide generation during acid exposure
• Capsule fill weight
• Powder flow and electrostatic behavior
• Container-closure integrity
• Stability under high humidity
• Reconstitution performance
• Taste and mouthfeel

Packaging is a critical part of the product. High-barrier blister packs, desiccants, foil sachets, and tightly controlled bottle systems may be necessary. A lower-cost bottle can undermine shelf life even when the formulation is chemically sound.

Geographic expansion adds regulatory variation. The United States, European Union, Canada, Japan, and emerging markets may differ in accepted excipients, sodium labeling, OTC classification, pediatric requirements, stability conditions, and rules governing immediate-release proton-pump inhibitors. A formulation optimized for U.S. OTC distribution may require reformulation or new data for other jurisdictions.

How does omeprazole/sodium bicarbonate compare with conventional omeprazole?

Omeprazole/sodium bicarbonate has a distinct formulation proposition but competes against lower-cost, widely available delayed-release omeprazole.

Factor	Omeprazole/sodium bicarbonate	Conventional omeprazole
Differentiation	Bedtime and immediate-release positioning	Established standard therapy
Excipient burden	High bicarbonate mass	Enteric coating and pellet excipients
Manufacturing	High-dose blending and moisture control	Pelletization and coating
Sodium exposure	Material	Generally lower from formulation excipients
Patient convenience	Capsule or suspension options	Broad capsule and tablet availability
Brand opportunity	Stronger for specific use cases	Strong generic price pressure
Patent opportunity	Reformulation and delivery claims	Many mature formulation pathways
OTC competition	Direct and intense	Very broad

The product is most attractive where the delivery system solves a clear patient problem. A new entrant should not rely on omeprazole as the sole differentiator.

Key Takeaways

• Sodium bicarbonate is both a functional excipient and a gastric-acid neutralizer.
• The platform enables immediate-release omeprazole without conventional enteric-coated pellets.
• The principal technical risks are moisture sensitivity, dose uniformity, high bicarbonate loading, taste, and packaging.
• Original core patent protection has substantially aged, making formulation execution and commercial positioning more important.
• Current Orange Book listings and Paragraph IV exposure must be assessed against the specific reference product and date.
• Stronger opportunities include reduced-sodium systems, palatable suspensions, chewables, orally disintegrating formats, and dysphagia-focused products.
• The most defensible IP strategy combines composition, dosage-form, manufacturing, packaging, and method-of-use claims with process trade secrets.
• Conventional omeprazole, esomeprazole, lansoprazole, and private-label OTC products create substantial price and distribution pressure.
• Packaging and moisture control can determine commercial viability even when the formulation is chemically effective.

FAQs

Is sodium bicarbonate an active ingredient in omeprazole/sodium bicarbonate products?

Sodium bicarbonate is generally classified as an inactive ingredient in the pharmaceutical product, but it has a functional pharmacologic role by neutralizing gastric acid and creating an alkaline environment that protects omeprazole.

Can a company launch a generic omeprazole/sodium bicarbonate capsule?

A company may pursue an ANDA if it can satisfy FDA requirements for pharmaceutical equivalence, bioequivalence, manufacturing, stability, labeling, and patent certification. The applicant must evaluate current Orange Book patents and any applicable Paragraph IV litigation risk.

Is a low-sodium omeprazole formulation commercially attractive?

Yes. Lower sodium exposure could address a limitation of the current platform, but the product would need to preserve omeprazole stability and demonstrate equivalent or clinically acceptable performance.

Are excipient patents available for omeprazole products?

Yes. Patentable subject matter may include novel buffering systems, moisture-control compositions, taste masking, particle engineering, suspension technology, packaging, and manufacturing processes. Patentability depends on novelty, nonobviousness, enablement, and claim scope.

Does omeprazole/sodium bicarbonate have biosimilar risk?

No. Omeprazole is a small-molecule drug, not a biologic. Competitive risk arises from ANDA-based generics, OTC products, private-label products, and reformulations rather than biosimilars.

References

1. U.S. Food and Drug Administration. (2023). Zegerid (omeprazole and sodium bicarbonate) prescribing information. FDA.
2. U.S. Food and Drug Administration. (2023). DailyMed and inactive ingredient information for omeprazole and sodium bicarbonate products. FDA.
3. U.S. Patent and Trademark Office. (n.d.). Patent Center and Patent Examination Data System records for omeprazole and alkaline pharmaceutical compositions. USPTO.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
5. Santarus, Inc. (2004). U.S. patent filings and regulatory submissions relating to immediate-release omeprazole and sodium bicarbonate compositions. U.S. Patent and Trademark Office.
6. Bausch Health Companies Inc. (2023). Annual report and product information relating to Zegerid.
7. U.S. Food and Drug Administration. (2024). ANDA approvals, patent certifications, and Hatch-Waxman exclusivity framework. FDA.